Clinical applications of donor lymphocyte infusion from an HLA-haploidentical donor: consensus recommendations from the Acute Leukemia Working Party of the EBMT

Bhagirathbhai Dholaria, Bipin N. Savani, Myriam Labopin, Leo Luznik, Annalisa Ruggeri, Stephan Mielke, Monzr M. Al Malki, Piyanuch Kongtim, Ephraim Fuchs, Xiao-Jun Huang, Franco Locatelli, Franco Aversa, Luca Castagna, Andrea Bacigalupo, Massimo Martelli, Didier Blaise, Patrick Ben Soussan, Yolande Arnaud, Rupert Handgretinger, Denis-Claude Roy, Paul O’Donnell, Asad Bashay, Scott Solomon, Rizwan Romee, Philippe Lewalle, Jorge Gayoso, Michael Maschan, Hillard M. Lazarus, Karen Ballen, Sebastian Giebel, Frederic Baron, Fabio Ciceri, Jordi Esteve, Norbert-Claude Gorin, Alexandros Spyridonidis, Christoph Schmid, Stefan O. Ciurea, Aron Nagler and Mohammad Mohy.

ABSTRACT

Donor lymphocyte infusion has been used in the management of relapsed hematologic malignancies after allogeneic hematopoietic cell transplantation. It can eradicate minimal residual disease or be used to rescue a hematologic relapse, being able to induce durable remissions in a subset of patients. With the increased use of haploidentical
hematopoietic cell transplantation, there is renewed interest in the use of donor lymphocytes to either treat or prevent disease relapse post transplant. Published retrospective and small prospective studies have shown encouraging results with therapeutic donor lymphocyte infusion in different haploidentical transplantation platforms. In this consensus paper, finalized on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize the available evidence on the use of donor lymphocyte infusion from haploidentical donor, and provide recommendations on its therapeutic, pre-emptive and prophylactic use in clinical practice.

**Introduction**

Allogeneic hematopoietic cell transplantation (allo-HCT) remains an important therapeutic option for a wide number of both hematologic malignancies and non-hematologic disorders. With improvements in conditioning regimens, graft-versus-host disease (GVHD) prophylaxis and supportive care, leading to a reduced risk of transplant-related mortality, disease relapse has become the foremost cause of mortality after allo-HCT. The cumulative incidence of relapse (CIR) after allo-HCT for acute leukemia can be as high as 40-50% with only 10-15% long-term survival in patients experiencing leukemia recurrence. Strategies aimed at preventing and/or treating disease relapse have the greatest potential to improve transplant outcomes. Donor-lymphocyte infusion (DLI) has an established role in the management of disease relapse after allo-HCT. Unmanipulated DLI is a form of immunotherapy, which can induce durable remissions by enhancing the graft-versus-tumor (GvT) effect. Efficacy of DLI varies by type and burden of the disease. DLI is more effective in chronic myeloid leukemia (CML), leading to complete remission (CR) in 70-80% of patients in hematologic or cytogenetic CML relapse, whereas less than 40% of acute leukemia patients respond to DLI. A study by Schmid et al. using the European Society for Blood and Marrow Transplantation (EBMT) registry showed DLI was associated with improved survival of patients with AML in the first hematologic relapse after allo-HCT, but 2-year overall survival (OS) was only 15% if DLI was given in the setting of active disease. Preemptive DLI for mixed chimerism or molecular disease relapse and prophylactic DLI for high-risk hematologic malignancies have also been studied with promising results in the setting of human leukocyte antigen (HLA)-matched allo-HCT.

Allo-HCT from an HLA-haploidentical related donor (haplo-HCT) has emerged as a suitable alternative for those patients who need an allograft but who lack an HLA-matched related or unrelated donor. Several T-cell depleted and T-cell replete haploidentical transplant strategies are applied today. In T-cell replete haploidentical stem cell transplantation, the use of post-transplant cyclophosphamide (PTCy) has rapidly increased across the globe due to its logistical simplicity and efficacy. Another T-cell replete haplo-HCT platform is granulocyte colony stimulating factor (GCSF)-antithymocyte globulin (ATG)-based or “GIAC” protocol [GCSF-stimulation of the donor; intensified immunosuppression through post-transplantation cyclosporine (CSA), mycophenolate mofetil (MMF), and short-course methotrexate (MTX); anti-thymocyte globulin (ATG); and combination of peripheral blood stem cells (PBSC) and bone marrow (BM) allografts] initially developed at the Peking University. Today’s T-cell depleted strategies derive from the mega-dose CD34+ protocol developed at the Perugia University and represent a historical standard in T-cell depletion. From this platform, several other T-cell depleted strategies have evolved, such as CD3/CD19 cell depletion and α-β-T/CD19-B cell depletion. The adoptive transfer of selectively allo-depleted or gene-modified T cells with a suicide switch after T-cell depleted transplantation have further optimized this transplant form and are now being investigated in large randomized trials in comparison with PTCy.

Haplo-HCT with PTCy has shown comparable clinical outcomes to matched unrelated donor allo-HCT in retrospective analyses with a significantly lower risk of chronic GVHD in myeloid and lymphoid malignancies, regardless of whether the graft was obtained from BM or mobilized PBSC. There is concern that DLI from a haploidential donor (haplo-DLI) may pose an increased risk for GVHD, given the higher degree of HLA disparity between the donor and recipient. However, a greater HLA-disparity may also be beneficial in promoting a stronger GvT effect. Another advantage is that a related haploidential donor is, in most cases, readily available and collection is faster than a registry-based unrelated donor. While the experience with haplo-DLI is limited, and there are many uncertainties around its clinical application, it can be a powerful tool to manage a disease relapse after haplo-HCT. Nonetheless, it should be emphasized that haplo-DLI after T-cell depleted transplantation without full immune reconstitution may have very different effects than after T-cell replete transplantation and may require completely different dosing strategies. Therefore, in the absence of data from prospective clinical trials, general recommendations cannot be made.

In this review, we summarize the published experience with haplo-DLI and provide recommendations regarding its use in various clinical settings (therapeutic vs. prophylactic), use of chemotherapy before DLI, optimal cell dose, and concurrent immunosuppression management. Newer strategies using cellular engineering, donor-derived natural killer (NK) cells and pharmacological immunomodulation are also discussed.

**Therapeutic haplo-donor-lymphocyte infusion: hematologic relapse**

Previously published retrospective studies have suggested that outcomes of haplo-DLI in patients with hematologic relapse are comparable to standard DLI from an HLA-matched donor. The incidence of DLI-associated GVHD also appears to be similar regardless of donor type. Possible explanations, at least when used late post transplant, are the use of lower cell dose and presence of donor-derived tolerogenic cells in the recipient,
which may reduce their alloreactivity and, thus, the risk of GVHD. The type of haplo-HCT protocol may influence outcomes of subsequent haplo-DLI. The current therapeutic haplo-DLI experience is limited to haplo-HCT/PTCy or a ‘GCSC-ATG-based protocol’. Table 1 summarizes the published studies using DLI from a haploidential donor.

**Therapeutic donor-lymphocyte infusion in T-cell replete haplo-hematopoietic cell transplantation**

Zeidan et al. retrospectively reported results of haplo-DLI in 40 patients [minimal residual disease (MRD)/loss of chimerism (LOC): n=5; hematologic relapse: n=35] after a haplo-HCT/PTCy with BM graft. At the median follow up of seven months, CR was achieved in 50% of patients (CR after a hematologic relapse: 26% and acute GVHD (aGVHD) occurred in 25% of them. At time of last follow up, six patients were alive in CR for over a year after the intervention. The cell dose in most DLI was 1x10^6 CD3+ cells/kg and the majority of patients received cytoreductive chemotherapy before DLI. Subsequently, two similar reports showed that haplo-DLI after chemotherapy successfully resulted in CR in approximately 50% of the patients with a subset of long-term survivors. The incidence of grade 2-4 aGVHD was approximately 30%, and only 5% of patients developed grade 3-4 aGVHD. No patient (0%) developed extensive chronic GVHD (cGVHD). None of these studies used immunosuppression for GVHD prophylaxis after haplo-DLI. Disease responses and GVHD rates were comparable between patients who received BM versus a PBSC graft. Patients with relapsed Hodgkin lymphoma appear to have relatively better disease responses to haplo-DLI compared to those with acute leukemia (40% vs. 83%). In a smaller retrospective study (n=21) published by Goldsmith et al., the authors showed that patients with extra-medullary disease relapse had a better relapse-free survival (RFS) compared to those with marrow relapse (4-month RFS 43% vs. 8%). The group at Peking University has developed a haplo-DLI protocol using GCSC-primed peripheral blood progenitor cells (GBPFC) with short-term immunosuppression. They have used a higher cell dose (1x10^6 to 1x10^7 CD3+ cells/kg) than that used in haplo-DLI in the setting of allo-HCT/PTCy (1x10^5 to 1x10^6 CD3+ cells/kg). An earlier prospective study using GBPFC without immunosuppression resulted in a high incidence of severe GVHD (grade 3-4 aGVHD 30%, extensive cGVHD 30%), resulting in 2-year disease-free survival (DFS) of 40% and non-relapse mortality (NRM) of 25%. Subsequent studies used cytoreductive chemotherapy before GBPFC infusion (chemo-DLI) followed by GVHD prophylaxis with low-dose weekly MTX or CsA for 6-8 weeks. A retrospective report by Yan et al. on 55 patients with relapsed acute leukemia showed 3-year DFS, NRM, and OS of 24%, 13%, and 25%, respectively. A total of 76% of patients achieved CR (MRD negative CR: 55%). Relapse after achieving CR following chemo-DLI was a major problem, resulting in poor long-term survival. In spite of the limitations of cross-study comparison, outcomes of chemo-GBPFC infusion with short-course immunosuppression are comparable to unmanipulated haplo-DLI after haplo-HCT/PTCy.

**Pre-emptive haplo-donor-lymphocyte infusion: minimal residual disease, mixed-donor chimerism**

**Impact of minimal residual disease and mixed-chimerism on haplo-hematopoietic cell transplantation outcomes**

Strategies are being explored to reliably predict the risk of disease relapse after an allo-HCT in the hope of implementing pre-emptive treatments. The presence of MRD before or after allo-HCT is associated with significantly increased risk of relapse and reduced survival in both acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML). Canaani et al. looked at pre-haplo-HCT MRD positivity in AML patients and showed its negative correlation with leukemia-free survival. Low donor T-cell chimerism [mixed-chimerism (MC)] after an allo-HCT is also associated with poor donor-derived immune reconstitution and increased risk of disease relapse, especially after myeloablative conditioning. In patients with AML/MDs who underwent myeloablative allo-HCT, donor T-cell chimerism <35% at day (d)+90 and d+120 was associated with increased risk of 3-year disease progression (HR=2.1, P=0.04). Koreth et al. reported that d+100 total donor chimerism <90% was associated with increased risk of relapse (HR= 2.54, P<0.001) and lower OS (HR=1.50, P=0.009) in patients after a reduced-intensity allo-HCT. Pre-emptive DLI from a full matched donor for MRD and MC appears to be safe and effective in improving disease-specific outcomes.

**Pre-emptive donor-lymphocyte infusion in T-cell replete haplo-hematopoietic cell transplantation**

In the previously mentioned retrospective study by Zeidan et al., 3 of 4 patients who received haplo-DLI for MRD entered CR. Similarly, other reports showed higher response rates in patients who received haplo-DLI for MRD or MC compared to the administration at the time of hematologic relapse. Yan et al. reported comparative outcomes of prospective studies of standard-risk acute leukemia and MDS patients with persistent MRD after allo-HCT (haploidentical donor, n=29; matched donor, n=27), who received low-dose interleukin-2 (IL-2) or pre-emptive DLI. The latter was associated with reduced 3-year CIR compared to IL-2 alone (28% vs. 64%; P=0.001). In another retrospective study by Mo et al., 101 patients (haplo-HCT, n=56) received chemo-DLI for persistent MRD after an allo-HCT. Three-year CIR, NRM, and OS were 40%, 10%, and 52%, respectively. Patients who cleared their MRD within 30 days after pre-emptive chemo-DLI had lower relapse rates compared to those with persistent MRD beyond 30 days (20% vs. 47%; P=0.001). It should be noted that the published data on pre-emptive haplo-DLI for MC is limited to a few patients and further studies are needed to establish its role in preventing disease relapse.

It is important to monitor for MRD after allo-HCT as DLI is probably more effective when administered for MRD only compared overt hematologic relapse. Retrospective studies have shown that persistent MRD post-transplant is associated with high relapse rate and poor outcomes, and the eradication of MRD improves survival. Comparative studies are needed between DLI and other systemic therapies in order to develop disease-
## Table 1. Donor-lymphocyte infusion from a haploidentical donor.

| Study                | N. of patients (prospective/retrospective) | Diagnosis            | Indication for DLI | Treatments before DLI | CD3+ dose/kg | N. of DLI (median) | Disease response | Rate of GvHD | Survival | Notes                  |
|---------------------|------------------------------------------|----------------------|--------------------|-----------------------|---------------|-------------------|------------------|--------------|----------|------------------------|
| **T-cell depleted haplo-HCT** |                                          |                      |                    |                       |               |                   |                  |              |          |                        |
| Lewalle et al. (2003)* | 12 (prospective)                          | AML=5                | Prophylactic=12    | None                  | 1-4x10⁶       |                   |                  | 58%          |          | 1-yr RFS=50%, 1-yr OS=50%, NRM=0% T-B-cell depleted graft |
| Dodero et al. (2009)** | 23 (prospective)                          | Lymphoma CLL        | Prophylactic-23    | None                  | 2-15x10⁴      | 2                | NA              | aGvHD=26% (grade 3-4=9%) cGvHD=15% (extensive=12%) 2-yr PFS=45% 2-yr OS=44% NRM=28% | CD8+ T-cell depleted DLI |
| Martelli et al. (2014)** | 43 (prospective)                          | AML=33               | Prophylactic-43    | None                  | Tₚ=2.5x10⁴±1.1 Tₚₚ=1.1x10⁴±0.6 | 1                | NA              | aGvHD (grade 2)=15% cGvHD=16% (extensive=7%) CI NRM=60% 46-m relapse =5% Tₚ on day-4, Tₚₚ on day 0 |
| Gilman et al. (2018)** | 34 (prospective)                          | AML/MDM=13           | Prophylactic-34    | None                  | 3-5x10⁴      | 1                | NA              | aGvHD (grade 3-4)=4% cGvHD=16% (extensive=7%) 2-yr OS=63% 2-yr NRM=25% | Post-DLI-GvHD ppx=100% |
| **T-cell replete haplo-HCT** |                                          |                      |                    |                       |               |                   |                  |              |          |                        |
| Or et al. (2006)** | 28 (haplo-26/MMUD-2) (retrospective)      | AML=12               | Prophylactic-6     | Therapeutic-22        | 1x10⁸ to 15x10⁸ | 1-7 (1)          | CR=18%           | 46%          | NRM=11% |                        |
| Huang et al. (2007)** | 20 (prospective)                          | AML=7                | Therapeutic=20     | CT=9 TKI=2            | 0.07-4.3x10⁶ | 1-3 (1)          | CR=75%           | aGvHD=55% (grade 3-4=30%) cGvHD=84% (extensive=30%) | Post-DLI-GvHD ppx=55% |
| Yan et al. (2012)** | 56 (haplo-29, matched related-28, MUD-1) (prospective) | AML=32               | Pre-emptive=56     | (MRD)                 | CT=32        | 0.75-2x10⁴      | 1               | aGvHD=31% (grade 3-4=4%) cGvHD=3% (extensive=44%) 3-yr DFS=56% 3-yr OS=56% 3-yr NRM=14% | Post-DLI-GvHD ppx=100% |
| Yan et al. (2012)** | 124 (retrospective)                       | AML=49               | Prophylactic=74    | Therapeutic/ pre-emptive=50(MRD) | CT=27        | 0.13-2.11x10⁴ | 1-4 (1)          | aGvHD=53% (grade 3-4=28%) 2-yr CIR=35% 2-yr OS=47% 2-yr NRM=34% In disease relapse, 2-yr CIR=45% 2-yr OS=19% 2-yr NRM=37% | Post-DLI-GvHD ppx=100% |
| Wang et al. (2012)** | 61 (retrospective)                        | AML=42               | Prophylactic=61    | CT=0%                 | 0.9-7.2x10⁴  | 1                | NA              | aGvHD=48% (grade 3-4=10%) cGvHD=39% (extensive=31%) 3-yr DFS=22% 3-yr OS=31% 2-yr NRM=38% | Post-DLI-GvHD ppx=100% |
| Yan et al. (2013)** | 50 (retrospective)                        | AML=29               | Therapeutic=50     | CT=100%               | 0.11-2.07x1** | NA              | CR=64%           | aGvHD=66% (grade 3-4=40%) cGvHD=44% (extensive=42%) | Post-DLI-GvHD ppx=100% |
| Yan et al. (2015)** | 55 (retrospective)                        | AML=18               | Therapeutic=55     | CT=100%               | 0.19-0.74x10⁴ | NA              | CR=76%           | aGvHD=44% (grade 3-4=11%) cGvHD=49% (extensive=42%) 3-yr DFS=24% 3-yr OS=25% 3-yr NRM=13% | Post-DLI-GvHD ppx=100% |
| Mo et al. (2016)** | 101 (haplo=58) (retrospective)            | AML/MDM=69           | Pre-emptive=101(MRD) | CT=100%               | 1.7-7.4x10⁴  | NA              | CR=78%           | aGvHD=49% (grade 3-4=8%) cGvHD=59% AML/MDM, 3-yr DFS=57% 3-yr OS=49% 3-yr NRM=11% | Post-DLI-GvHD ppx=100% |

continued on the next page
Donor lymphocyte infusion in haplo-HCT

| Study                      | N of patients (prospective/retrospective) | Diagnosis | Indication for DLI | Treatments before DLI | CD3⁺ dose/kg | N. of DLI (median) | Disease response | Rate of GvHD | Survival | Notes                  |
|----------------------------|------------------------------------------|-----------|--------------------|------------------------|--------------|-------------------|-----------------|---------------|----------|------------------------|
| Yan et al. (2016)***       | 47 (haplo=31) (prospective)              | AML=25    | Pre-emptive=47 (MRD) | CT=100%                | 1.5-6.4x10⁷  | 1-4               | NA              | aGvHD =19% | 1-yr DFS=71% | Post-DLI-GvHD ppx=100% |
|                            |                                          | ALL=22    |                    |                        |              |                   |                 | (grade 3-4=6%) | 1-yr NRM=9% | OS=78%          |
|                            |                                          |           |                    |                        |              |                   |                 | cGvHD =79%    | 3-yr OS=73% |
|                            |                                          |           |                    |                        |              |                   |                 | (≥moderate=60%)|          |                        |
|                            |                                          |           |                    |                        |              |                   |                 |              |          |                        |
| Yan et al. (2017)***       | 100 (haplo=62) (prospective)             | AML=59    | Prophylactic=100    | CT=0%                  | 1.8-6.6x10⁷  | NA                | NA              | NA           | 1-yr DFS=51% | Post-DLI-GvHD ppx=100% |
|                            |                                          | ALL=41    |                    |                        |              |                   |                 |              |          |                        |
|                            |                                          |           |                    |                        |              |                   |                 |              |          |                        |
| Ma et al. (2017)***        | 36 (retrospective)                       | AML/ALL/MDSCML | Therapeutic=36      | CT/TKI =100%           | NA           | NA                | CR=56%         | Grade 3.4 | 3-yr DFS=41% | Post-DLI-GvHD ppx=100% |
|                            |                                          |           |                    |                        |              |                   |                 | aGvHD =25%    | 3-yr OS=14% |
|                            |                                          |           |                    |                        |              |                   |                 | cGvHD =36%    |          |                        |
|                            |                                          |           |                    |                        |              |                   |                 |              |          |                        |
| Gao et al. (2018)***       | 31 (retrospective)                       | AML=21    | Prophylactic=31     | CT=0%                  | 0.4-6.8x10⁷  | 1                 | NA              | aGvHD =58% | 2-yr RFS=32% | Post-DLI-GvHD ppx=100% |
|                            |                                          | ALL=5     |                    |                        |              |                   |                 | (Grade 2-7%) | 2-yr NRM=33% |
|                            |                                          | CML=2     |                    |                        |              |                   |                 | cGvHD =39%    | 2-yr OS=40% |
|                            |                                          | Other=3   |                    |                        |              |                   |                 | (moderate=29%)|          |                        |
|                            |                                          |           |                    |                        |              |                   |                 |              |          |                        |
| Zeidan et al. (2014)***    | 40 (retrospective)                       | AML=16    | Therapeutic=35      | CT/RT = 70%            | 1x10⁹ to 1x10¹⁰ | 1-4(1)           | CR=30%         | aGvHD =25% | 8/12 responders | (67%) alive, in CR at 17.5 months |
|                            |                                          | ALL=3     |                    |                        |              |                   |                 | cGvHD =15%    |          |                        |
|                            |                                          | CML=1     |                    |                        |              |                   |                 | (extensive=5%)|          |                        |
|                            |                                          | Lymphoma=11 |                |                        |              |                   |                 |              |          |                        |
|                            |                                          | Other=9   |                    |                        |              |                   |                 |              |          |                        |
| Ghiso et al. (2015)***     | 42 (retrospective)                       | AML=22    | Therapeutic=22      | CT/RT = 100%           | 1x10⁹ to 1x10¹⁰ | 1-5 (mean=2.5)  | CR=36%         | aGvHD =33% | Median survival 36% | Leukemia, median response=4m(2-10), median survival =7m(1-15) |
|                            |                                          | ALL=9     |                    |                        |              |                   |                 | (grade 3-4=5%)|          |                        |
|                            |                                          | HL=10     |                    |                        |              |                   |                 | cGvHD =0%     |          |                        |
|                            |                                          | MM=1      |                    |                        |              |                   |                 |              |          |                        |
| Jaiswal et al. (2016)***   | 21 (prospective)                        | AML=21    | Prophylactic=21     | CT=0%                  | 9.2-110x10⁷  | 1-3               | NA              | Cum incident | 1.5-yr DFS=62% | Post-DLI-GvHD ppx=100% |
|                            |                                          |           |                    |                        |              |                   |                 | aGvHD =31%    | 1.5-yr OS=71% |
|                            |                                          |           |                    |                        |              |                   |                 | cGvHD =41%    |          |                        |
|                            |                                          |           |                    |                        |              |                   |                 |              |          |                        |
| Goldsmith et al. (2017)*** | 21 (retrospective)                       | AML/MDS=16 | Therapeutic=19      | CT=76%                 | 0.01-3x10⁷  | 1-5               | CR=32%         | aGvHD =33% | Hematologic relapse | BPSC haplo-HCT |
|                            |                                          |           |                    |                        |              |                   |                 | (grade 3-4=5%)|          |                        |
|                            |                                          |           |                    |                        |              |                   |                 | cGvHD =26%    |          |                        |
|                            |                                          |           |                    |                        |              |                   |                 | (extensive=0%)|          |                        |
|                            |                                          |           |                    |                        |              |                   |                 |              |          |                        |
| Cauchois et al. (2018)***  | 36 (retrospective)                       | AML/MDS=25 | Prophylactic=36     | CT=0%                  | 0.1-2.5x10⁷  | 1-3               | NA              | 1-yr CI of mod-severe | BPSC graft=31 |
|                            |                                          |           |                    |                        |              |                   |                 | aGvHD =33%    | 1-yr NRM=9% |
|                            |                                          |           |                    |                        |              |                   |                 | (grade 3-4=5%)|          |                        |
|                            |                                          |           |                    |                        |              |                   |                 | 1-yr OS=70%   |          |                        |

N: number; AML: acute myeloid leukemia; ALL: acute lymphoblastic leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndromes; MMU/M: mismatched unrelated donor; GvHD: ppx graft-versus-host disease prophylaxis; aGvHD: acute GvHD; cGvHD: chronic GvHD; OS: overall survival; DFS: disease-free survival; PFS: progression-free survival; NRM: non-relapse mortality; CT: chemotherapy; TKI: tyrosine kinase inhibitor; MRD: minimal residual disease; MC: mixed chimerism; NA not available; RT: radiation therapy; PBSC: peripheral blood stem cell; EM: extramedullary relapse; RF: relapse-free survival; haplo-HCT: haploidentical-hematopoietic cell transplant; matched: HLA-matched allo-HCT; MUD: HLA-matched unrelated donor; TCR regulatory Tcell; Tc: conventional T cells; CI: cumulative incidence; yr: year; m: months; NA: not available. *Granulocyte colony-stimulating factor (GCSF)-anti-thymocyte globulin (ATG)-based protocol and G-CSF primed peripheral blood progenitor cell (PBPC). †Haplo-HCT with post-transplant cyclophosphamide (PTCy) and GvHD + Haplo-HCT with PTCy and standard donor lymphocyte infusion (DLI). Pharmacology. Patients had salvage chemotherapy + therapeutic DLI for hematologic relapse, followed by pre-emptive DLI or persistent minimal residual disease (MRD); pt patient; mod: moderate; cum: cumulative; HL: Hodgkin lymphoma.
specific MRD management strategies. DLI should not be used in patients who have converted to host chimerism due to increased risk of marrow aplasia. An alternative strategy for such patients would be to undergo a second allo-HCT from the same or from a different donor. It is important to weigh the risk of GvHD and marrow aplasia versus the potential benefit of reducing the disease relapse when considering pre-emptive DLI for MRD or MC.

**Prophylactic haplo-donor-lymphocyte infusion**

Prophylactic DLI from a matched donor has been studied in patients with high-risk myeloid malignancies and was associated with improved disease-specific outcomes and low NRM. It can contribute to immune reconstitution and reduce the risk of infection, which is a major challenge after a T-cell depleted haplo-HCT. A matched-pair analysis by the EBMT showed improved OS in high-risk AML recipients who received prophylactic DLI from a matched donor (70% vs. 40% in controls; P=0.027). Inclusion criteria differ among published studies in their definition of high-risk disease. Most reports included patients with primary induction failure acute leukemia, high disease risk index, active disease before allo-HCT or the presence of high-risk mutations (i.e. TPS3, ASXL1, RUNXI) in myeloid malignancies.

One of the first experiences with prophylactic haplo-DLI was in the setting of autologous-HCT. Nagler et al. reported outcomes of 26 patients who received multiple haplo-DLI (with/without IL-2) after an autologous-HCT. This approach was feasible in inducing GvHD, but higher cell doses led to increased toxicity. The timing of prophylactic-DLI is also important as decreasing the interval between allo-HCT and DLI will likely increase the risk of aGvHD. The activity of ATG, given as a part of conditioning, may persist for weeks, and residual ATG may negatively impact prophylactically infused donor lymphocytes. At the same time, the administration of haplo-DLI as early as d+45 was feasible in single center studies. It may be reasonable to administer prophylactic haplo-DLI before d+90 given that median time to relapse after allo-HCT is approximately three months.

**Prophylactic donor-lymphocyte infusion in T-cell depleted haplo-hematopoietic cell transplantation**

Early experience with prophylactic haplo-DLI was with T-cell-depleted haplo-HCT where donor lymphocytes were infused after a CD34+ cell-selected graft to enhance immune reconstitution. Perruccio et al. showed that infusion of donor-derived non-alloreactive T cells specific for cytomegalovirus (CMV) and aspergillus resulted in the rapid development of T-cell responses against these pathogens without inducing GvHD. Another prospective study utilized CD8+ T-cell depleted DLI, which resulted in aGvHD in 26% of patients with 2-year PFS of 45%. Donor-derived T regulatory cells (Treg), co-infused with conventional T cells (Tcon) were shown to protect recipients against GvHD. In a prospective study, patients received Treg (d -4) followed by a megadose of CD34+ cells and Tcon on d0 from a haploidentical donor without any post-transplant immunosuppression. Only 15% of the patients developed ≥ grade 2 aGvHD and DFS was 56% at 18 months. In another prospective study by Gilman et al., 34 pediatric patients were infused an unmanipulated prophylactic haplo-DLI with MTX between d+50 and d+42 after a T-cell depleted/CD34+ selected haplo-HCT. The intervention was safe and 2-year NRM.

---

**Figure 1. Proposed treatment algorithm of therapeutic, pre-emptive and prophylactic donor-lymphocyte infusion (DLI) following T-cell replete haploidentical hematopoietic cell transplantation (HCT).**

| T-replete haplo-HCT for hematologic malignancy | Yes |
|-----------------------------------------------|-----|
| Hematologic relapse                           |     |
| No                                            |     |
| **Salvage therapy**                          |     |
| No response                                   |     |
| Complete remission                            |     |
| Observation                                   |     |

**THERAPEUTIC HAPLO-DLI**
- No evidence of HLA loss (consider second allo-HCT from different donor if HLA loss confirmed)
- Consider cytoreductive therapy before DLI
- Starting DLI dose 1x10^6 CD34 cells/kg
- Escalate dose by 0.5-1 kg with each DLI
- Repeat DLI every 4 to 6 weeks depending on MRD and GvHD status
- zTak/hypomethylating agent in eligible patients
- Taper immunosuppressive drugs as tolerated

**PRE-EMPTIVE HAPLO-DLI**
- Taper immunosuppressive drugs as tolerated
- Exclude patients with donor CD34 chimerism <50%
- Starting dose 1x10^7 CD34 cells/kg
- Repeated doses depending on GvHD and MRD status

**PROPHYLACTIC HAPLO-DLI**
- High-risk myeloid malignancy
- Starting dose 1x10^6 CD34 cells/kg
- Starting day+60 to ≥90 post-haplo-HCT
- Repeated doses depending on GvHD and MRD status

*Under a clinical trial*
and OS were 25% and 63%, respectively. Lewalle et al. reported the outcomes of 12 patients who received prophylactic haplo-DLI starting on d+28 after T/B-cell depleted haplo-HCT in a prospective study. One-year RFS, NRM, and OS were 50%, 0%, and 50%, respectively. Despite the encouraging results with prophylactic infusion of T-cell subset after a T-cell deplete/CD34+ selected haplo-HCT, its widespread adoption has been challenging as cell selection remains a labor-intensive and expensive process.

**Prophylactic donor-lymphocyte infusion in T-cell replete haplo-hematopoietic cell transplantation**

The Chinese group has led the way by incorporating prophylactic GPC in high-risk malignancies after a haplo-HCT with the GCSF-ATG-based protocol. In a retrospective study by Wang et al., patients with high-risk leukemia who underwent GPC infusion were compared to 27 patients who received routine care after an haplo-HCT. Prophylactic GPC was associated with lower relapse rate (36% vs. 55%; \( P=0.017 \)) and superior estimated 3-year survival (31% vs. 11%; \( P=0.001 \)) compared to routine care. There was no difference in NRM between the two groups. A prospective study by the same group enrolled 62 patients with high-risk acute leukemia. All patients received prophylactic GPC between d+45 and d+60 and further DLI were guided by MRD and GvHD status. Three-year DFS, NRM, and OS were 51%, 18%, and 49%, respectively. Acute and chronic GvHD were seen in 47% and 63% patients, respectively. Outcomes were similar between recipients of haploidentical (n=62) versus matched donor (n=38) prophylactic DLI.51

Jaiswal et al. reported their prospective experience with prophylactic GPC in the T-cell replete haplo-HCT/PTCy setting. Twenty-one patients with AML (not in remission) received up to three doses of haplo-GPC (d+21, d+35 and d+60). They were compared with 20 patients who received routine monitoring after haplo-HCT. At 18 months, CIR, PFS, and OS were 21% versus 66%; 62% versus 25% and 71% versus 35% in DLI and routine care cohorts, respectively. Incidence of aGvHD was 31%, while incidence of chronic GvHD was 41% after GPC infusions. NRM was equivalent between the groups.52 Recently, Cauchios et al. reported outcomes of 36 patients who received prophylactic haplo-DLI after a haplo-HCT/PTCy. One-year PFS and OS were 76% and 88%, respectively. The cumulative incidence of relapse was 16% and the incidence of DLI-associated GvHD was 33%.53

**Practical aspects of haplo-donor-lymphocyte infusion**

**Cell dose**

The CD3+ T-cell dose ranged from 0.01 to 8.8x10^8 mononuclear cells/kg in reports on therapeutic DLI from a matched donor. A study reported a relatively lower rate of GvHD with an escalating cell dose regimen versus a single bulk infusion of DLI from HLA-matched donors. Disease responses were similar between the two approaches.54 There was no dose-response relationship with GvHD or disease response rates in haplo-DLI in the setting of T-cell depleted haplo-HCT.20,25 The average starting dose for therapeutic haplo-DLI in the T-cell replete haplo-HCT/PTCy setting was 1 or 2 log lower than the standard DLI dose (1x10^10 CD3+ cells/kg) from HLA-matched donors. In a report on 40 patients, a cell dose of 1x10^6 CD3+ cells/kg was associated with grade 2-4 aGvHD in 17% of patients, and a CR rate of 27%.21 Goldsmith et al. used the same dose in 21 patients; only seven (33%) developed aGvHD (grade 3-4 aGvHD in 1 patient).50 These incidences of aGvHD were lower than those reported by the Chinese group using haplo-GPC at 1 to 2 log higher cell dose with the GCSF-ATG-based protocol. A starting cell dose of 1x10^6 to 1x10^7 CD3+ cells/kg was associated with grade 2-4 aGvHD in 50-60% (grade 3-4 aGvHD approximately 30%) of patients.51,53 Subsequent reports by Yan et al. showed a reduced incidence of aGvHD with the routine use of short-term GvHD prophylaxis after GPC infusion.53 Available data suggest that 1x10^6 CD3+cells/kg is a reasonable starting dose with appropriate repeated dose escalation every 4-6 weeks based on disease response and GvHD for therapeutc haplo-DLI in T-replete haplo-HCT with PTCy. Clinical trials are needed to establish the optimal timing and cell dose in prophylactic and T-cell depleted haplo-HCT settings. Published studies have used wide-ranging repeated non-escalating cell doses for pre-emptive or prophylactic DLI.52,57,24

**The end point of donor-lymphocyte infusion therapy**

It is important to establish the goal of DLI therapy beforehand as each DLI is associated with increased risk of GvHD. Patients with DLI-responsive relapse usually respond within 2-3 months.7 Repeated infusions of escalating doses of therapeutic DLI can be administered until CR is achieved (ideally an MRD-negative status) or the patient develops clinically significant GvHD. Patients should be evaluated for GvHD, donor chimerism and disease response after each DLI. Pre-emptive DLI for MRD persistence after allo-HCT may be stopped once the achievement of MRD negativity, significant GvHD or a hematologic relapse occurs. Donor chimerism should be assessed after each pre-emptive DLI for MC. Pre-emptive DLI may be stopped once ≥90% donor chimerism is achieved. As noted above, DLI can result in marrow aplasia in those patients who have converted to host chimerism. There is no standard duration of prophylactic DLI outside a clinical trial. In these circumstances, each dose of prophylactic haplo-DLI should be used with caution, balancing the risk of disease relapse and GvHD.

**Traditional donor-lymphocyte infusion versus granulocyte colony-stimulating factor-primepd peripheral blood progenitor cell infusion**

Standard DLI uses freshly collected unmanipulated donor lymphocytes. This approach privileges tumor alloreactivity over the risk of GvHD. GCSF promotes T-cell hypo-responsiveness in marrow grafts by increasing the number of plasmacytoid dendritic cells and monocytes. It also reduces the expression of co-stimulatory CD28/B7 on monocytes, B and T cells,70 promotes macrophage71 and T-cell polarization in the BM graft towards the more tolerogenic pattern. This property is maintained even after in vitro mixture of G-CSF primed BM and PBSC grafts.72,73 The Chinese group has reported their extensive experience with using GPC instead of unmanipulated DLI. Huang et al. reported the outcomes of 20 patients who received therapeutic GPC from hap-
lloidentical donors (the majority of whom received salvage therapy prior to GBPC infusion); CR was achieved in 75% of patients and the rates of acute and chronic GVHD were 55% and 64%, respectively. In another study of pre-emptive GBPC infusion for MRD after an allo-HCT (haploidentical related donor: n=29; matched-related donor: n=26), the incidences of acute and chronic GVHD were 31% and 43%, respectively. Routine debulking chemotherapy and short-term immunosuppression were used in most studies using GBPC. A prospective observational study by Jaiswal et al. used prophylactic-GBPC in the setting of T-cell replete haplo-HCT/PTCy. The incidence of aGVHD was comparable but cGVHD was higher than that reported with unmanipulated haplo-DLI in the PTCy setting. A recent report from Mexico showed that administration of G-CSF-primed whole blood units (median cell count 6.7x10^6 CD3 cells/kg) from haploidentical donors is safe, with disease responses and improvement in MC in a subset of patients. Whole blood units can potentially reduce the cost associated with haplo-DLI in developing countries. Long-term immune tolerance after PTCy may be enough to overcome the immunological barrier of haplo-DLI and G-CSF priming may not be required in this setting. Comparative studies between unmanipulated DLI versus GBPC in the setting of haplo-HCT/PTCy are needed.

Role of concurrent immunosuppression

Graft-versus-host disease is the main limiting toxicity of DLI, and short-term immunosuppression with DLI may improve the safety of DLI. Yan et al. reported aGVHD in 31% of patients after pre-emptive GBPC infusion for MRD persistence after T-cell replete haplo-HCT. All patients received CSA or low-dose MTX for 6-8 weeks after GBPC. There was no difference in acute and chronic GVHD rates between CSA and MTX. MTX was associated with lower relapse rate (38% vs. 81%; P=0.029) and better DFS (52% vs. 16%; P=0.06). Patients who received MTX had higher absolute lymphocyte count compared to those who received CSA, which may have contributed to better GVTr effect. The same group also showed that patients receiving GVHD prophylaxis for 6-8 weeks had a lower cumulative incidence of grade 3-4 aGVHD than patients receiving prophylaxis for 4-6, 2-4, and <2 weeks (9%, 14%, 52%, and 50%, respectively; P=0.018). In a retrospective study, Mo et al. used pre-emptive chemodLI for MRD persistence along with routine prophylaxis with CSA or MTX (haploidentical donor 6-8 weeks; matched donor 4-6 weeks). The incidence of aGVHD was only 9% (grade 3-4 aGVHD: 4%) in their cohort of 101 patients. It is important to note here that haplo-DLI without concurrent immunosuppression in the T-cell replete haplo-HCT/PTCy setting has been reported to have a similar incidence of GVHD compared to the GCSF-ATG-based haplo-HCT protocol, which routinely uses prophylactic immunosuppression with DLI. The potential impairment of the DLI-mediated GVTr effect by CSA or MTX is a concern when managing a hematologic relapse. It is reasonable to add short-term MTX after a pre-emptive or prophylactic haplo-DLI, especially in patients with a history of GVHD. There are no data available on concurrent immunosuppression with therapeutic haplo-DLI in the T-cell replete haplo-HCT/PTCy setting.

Combination of systemic therapies with donor-lymphocyte infusion

Administration of salvage therapy before the infusion of DLI may improve its efficacy by reducing the tumor burden and supporting in vivo expansion of infused T cells. In this regard, chemotherapy helps eliminate regulatory donor T cells and create a favorable immunological environment for DLI by increasing serum levels of IL-7 that favors peripheral expansion of T cells. In the retrospective study by Zeidan et al., patients who received a cytoxic therapy had better CR rates compared to those who received unmanipulated haplo-DLI without any preceding therapy (39% vs. 8%). This beneficial effect of pre-DLI chemotherapy was not seen in a similar report by Goldsmith et al.

The downside of pre-DLI chemotherapy is tissue injury and inflammatory cytokine surge which may increase the risk of GVHD, especially when used closer to the allo-HCT. Intensive chemotherapy after an allo-HCT is poorly tolerated, and infectious complications are common. Recently, hypomethylating agents (i.e. azacitidine, decitabine) have been used with DLI for relapsed AML/MDS. Azacitidine can induce allogeneic CD8 T-cell response by enhancing the expression of epigenetically silenced tumor-associated antigens. A combination of a hypomethylating agent and DLI is safe with no apparent increase in GVHD or infection risk compared to DLI-alone. In a prospective study using azacitidine with DLI for relapsed disease after HLA-matched allo-HCT, the CR rate was 23% and the 2-year OS was 17%. Another retrospective study utilizing decitabine followed by DLI for relapsed myeloid malignancies showed an overall response rate of 25% with 2-year OS of 11%. Drugs targeting specific molecular anomalies (BCR-ABL1, FLT3-ITD, IDH1, IDH2) are increasingly being incorporated in the treatment of disease relapse or as maintenance therapy after allo-HCT. These drugs are safer compared to traditional salvage chemotherapy and may provide benefit when administered in combination with DLI.

Immune escape after haplo-hematopoietic cell transplantation

Recent data have shed light on mechanisms of immune escape causing disease relapse after haplo-HCT. In haplo-SCT, HLA haplotype mismatched in the donor/recipient pair was replaced by a shared parent haplotype (uniparental disomy) in 5 of 17 patients with relapsed AML post-haplo-HCT. In a subsequent retrospective analysis of 69 patients who relapsed after haplo-HCT, mismatched-HLA haplotype loss accounted for 33% of the relapses. Based on retrospective studies, a second allo-HCT using a donor with a different mismatched haplotype or a mismatched unrelated donor may induce a better GVTr effect compared to same donor from the first haplo-HCT. At present, there is no standardized method of detecting loss of mismatched HLA haplotype in leukemic cells. HLA-allele specific quantitative polymerase chain reaction is required to quantify recipient- and donor-specific alleles to confirm uniparental disomy in low-burden disease relapse. Historically speaking, most patients receiving therapeutic DLI relapse and succumb to their disease. Close monitoring of MRD and donor chimerism after a successful therapeutic haplo-DLI is important to identify the
patients who are at high-risk of subsequent relapses. Mo et al. reported that patients with persistent MRD after DLI had increased relapse risk (P=0.001), resulting in poor DFS (P=0.004). In a prospective study of 47 patients (66% received haplo-HCT), MRD-guided repeated administration of pre-emptive chemo-DLI was effective in reducing the risk of subsequent relapse after achieving initial disease response. The one-year CIR, DFS, and OS were 22%, 71%, and 78%, respectively (Figure 1).57

**Future directions**

**Donor-derived natural killer cells**

Natural killer cells may play a role in tumor alloreactivity in the setting of mismatched or haploidentical transplant. A recent study showed a marked reduction in donor-derived NK cells in the recipients of PTCy, leading to blunting of NK-cell alloreactivity.59 In a pilot study, prophylactic infusion of CD56+/CD38 cells after haplo-HCT/PTCy in patients with refractory active disease was safe and associated with rapid immune reconstitution.60 The same group used prophylactic DLI primed with abatacept (CTLA4Ig), which selectively suppresses T-cell alloreactivity without interfering with NK-cell activation. Abatacept with DLI was associated with reduced incidence of aGVHD (10% vs. 31%) and improved relapse-free survival compared to prophylactic DLI alone.61 In a phase I study by Ciurea et al., donor-derived NK cells expanded ex vivo were infused prophylactically before and after haplo-HCT in high-risk myeloid malignant. The intervention was safe and associated with improved NK-cell number and function, lower viral infections, and low relapse rate when compared to a historical control group.62 Several methods to enhance NK-cell alloreactivity, including combination with immunomodulatory drugs,62 use of cytokine-activated NK cells,62 and selection of alloreactive single KIR+ NK cells,62 are under investigation.

**Engineered donor-lymphocyte infusion**

Different strategies are being explored to modify DLI composition and reduce the risk of GVHD while maintaining antitumor activity. ATIR101 is a haplo-DLI product with alloreactive T cells depleted by ex vivo photodepletion.63 In a pooled analysis of two prospective trials, 57 patients received prophylactic ATIR101 after T-cell depleted haplo-HCT. One-year relapse rate, NRM and OS were 8%, 53% and 58%, respectively. Interestingly, aGVHD (grade 1-4) and severe cGVHD were seen in 5% and 0% of the patients, respectively.64 Alloenergized DLI generated ex vivo was infused on d+35 after a CD34-selected haplo-HCT in a phase I study. These donor lymphocytes with the reduced donor-specific alloreactivity expanded in vivo and contributed to immune reconstitution.65 Another strategy is to insert an inducible suicide gene in donor lymphocytes so that they can be selectively eliminated to treat DLI-associated GVHD.66 A recent analysis on 100 children with acute leukemia given a titrated number of donor T cells transduced with the inducible caspase-9 safety switch after haplo-HSCT showed an 82% probability of relapse-free survival.67 Chimeric antigen receptor T-cell (CAR-T) therapy has emerged as a potent form of adoptive cellular therapy. Two CD19 CAR-T-cell therapies have been approved by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for relapsed/refractory high-grade B-cell lymphoma and B-ALL.99,100 Prophylactic infusion of CD19 CAR-T cells from a haploidentical donor was found to be safe with only mild aGVHD in one report.101 There are reports of therapeutic or pre-emptive donor-derived CAR-T-cell infusion with a small number of patients achieving durable remissions. CAR-T-cell-associated GVHD appears to be rare and of mild severity.102 Selective depletion of CD3+ αβ-TCR+ T cells (thought to be the principal mediators of GVHD) to enrich DLI with CD3+ γδ-TCR+ T cells and CD3+ CD56+ NK cells is also an attractive strategy to reduce the risk of GVHD while maintaining tumor alloreactivity.103 Maschan et al. infused low-dose (1x10⁶ CD3+cells/kg) CD45RA-depleted DLI (memory T cell) in 25 patients after TCR αβ-depleted haplo-HCT. The intervention was safe and associated with the expansion of cytomegalovirus-specific T cells in the recipients.104

**Conclusion**

- Unmanipulated DLI from a haploidentical donor appears to be relatively safe and reasonably effective in patients who relapse after a T-cell replete haplo-HCT. Patients given haplo-DLI should be enrolled in a clinical trial whenever possible, as data regarding optimal cell dose, timing and role of concurrent systemic therapies with haplo-DLI are limited. Information about the application of unmanipulated DLI after T-cell depleted transplantation is limited, which is why dosing should be managed with caution.
- The risk of GVHD after unmanipulated DLI in the haplo-HCT/PTCy setting is comparable to an unmanipulated DLI from an HLA-matched donor.
- Cytoreductive therapy prior to DLI from a haploidentical donor should be considered in patients with a hematologic relapse after haplo-HCT.
- Pre-emptive haplo-DLI may play a role in reducing disease relapse in patients with persistent MRD or mixed-donor chimerism after haplo-HCT; however, more studies are needed.
- Patients with high-risk myeloid malignancies may benefit from a prophylactic haplo-HCT, which should ide-
ally be used in the setting of a clinical trial.

- The administration of manipulated DLI after T-cell depleted or T-cell replete haploidentical transplantation, such as allogeneic or gene-modified T cells, should only be performed in the setting of a clinical trial.
- Patients should be monitored closely with frequent disease-specific MRD testing and donor-chimerism after DLI administration.
- Mismatched-HLA allele loss was detected in one-third of leukemia relapses after a haplo-HCT. Such patients are unlikely to benefit from DLI from the original donor. A second allo-HCT from a related donor with a different mismatched haplotype or a mismatched unrelated donor may be considered if HLA-loss is confirmed.

Acknowledgments
The authors would like to thank Vidya B. Pai, MD, for assistance with proofreading.

References
1. Bejanian Y, Weisdorf DJ, Logan BR, et al. Survival of patients with acute myeloid leukemia relapsing after allogeneic hematopoietic cell transplantation: a center for international blood and marrow transplant research study. Biol Blood Marrow Transplant. 2015;21(5):454-459.
2. Dholaria B. Different Mismatched Haplo-HCT: A reality or a myth? Bone Marrow Transplant. 2016;51(5):663-667.
3. Ciurea SO, Labopin M, Socie G, et al. Relapse and survival after transplantation for complex karyotype acute myelogenous leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation and the University of Texas MD Anderson Cancer Center. Cancer. 2018;124(10):2134-2141.
4. Kolb HJ, Mittermuller J, Clemm C, et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood. 1990;76(12):2462-2465.
5. Fanti AR, Gonder K, Lamb L, et al. Immunotherapy with donor leukocyte infusions for patients with relapsed acute myeloid leukemia following partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 1995;15(6):979-981.
6. Sica S, Di Mario A, Salutari P, et al. Chemotherapy and recombinant human granulocyte colony-stimulating factor primed donor leukocyte infusion for treatment of relapse after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1995;16(5):483-485.
7. Deol A, Lums LG. Role of donor lymphocyte infusions in relapsed hematological malignancies after stem cell transplantation revisited. Cancer Treat Rev. 2016;36(7):528-538.
8. Chalandon Y, Passweg JR, Schmid C, et al. Outcome of patients developing GVHD after DLI given to treat CML relapse: a study by the Chronic Leukemia Working Party of the EBMT. Bone Marrow Transplant. 2010;45(5):558-564.
9. Takami A, Yano S, Yokoyama H, et al. Donor lymphocyte infusion for the treatment of relapsed acute myeloid leukemia after allogeneic hematopoietic stem cell transplantation: a retrospective analysis by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation. Biol Blood Marrow Transplant. 2014;20(11):1785-1790.
10. Schmid C, Labopin M, Nagler A, et al. Donor lymphocyte infusion in the treatment of first hematological relapse after allogeneic stem-cell transplantation in adults with acute myeloid leukemia: a retrospective risk factors analysis and comparison with other strategies by the EBMT Acute Leukemia Working Party. J Clin Oncol. 2007;25(1):4958-4965.
11. Jedlickova Z, Schmid C, Koeneczke C, et al. Long-term results of adjuvant donor lymphocyte transfusion in AML after allogeneic stem cell transplantation. Bone Marrow Transplant. 2016;51(5):663-667.
12. Haines BL, Blessing JJ, Davies SM, et al. Outcomes of donor lymphocyte infusion for treatment of mixed donor chimerism after a reduced-intensity preparative regimen for pediatric patients with nonmalignant diseases. Biol Blood Marrow Transplant. 2015;21(2):288-292.
13. Lige M, Triantafyllou E, Tinakiou M, et al. High alloreactivity of low-dose prophylactic donor lymphocyte infusion in patients with acute leukemia undergoing allogeneic hematopoietic cell transplantation with an almsotuzumab-containing conditioning regimen. Biol Blood Marrow Transplant. 2015;19(1):75-81.
14. Passweg JR, Baldomero H, Bader P, et al. Hematopoietic stem cell transplantation in Europe 2014: more than 40 000 transplants annually. Bone Marrow Transplant. 2016;51(6):786-792.
15. Kanasty CG, Fuchs EJ, Luznik L. Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol. 2016;13(1):10-24.
16. Huang XJ, Liu DH, Liu KY, et al. Haploidentical hematopoietic stem cell transplantation without in vitro T-cell deple-tion for the treatment of hematological malignancies. Bone Marrow Transplant. 2006;38(4):291-297.
17. Ciceri F, Labopin M, Aversa F, et al. A survey of fully haploidentical hematopoietic stem cell transplantation in adults with high-risk acute leukemia: a risk factor analysis of outcomes for patients in remission at transplantation. Blood. 2008;112(9):3574-3581.
18. Locatelli F, Merli P, Pagliara D, et al. Outcome of children with acute leukemia given HLA-haploidentical HSC T after alpha-beta T-cell and B-cell depletion. Blood. 2017;130(5):677-683.
19. Lang FJ, Schlegel FC, Meisel R, et al. Safety and Efficacy of Totalpha/Beta and CD19 Depleted Haploidentical Stem Cell Transplantation Following Reduced Intensity Conditioning in Children: Results of a Frequent Multicenter Phase I/II Clinical Trial. Blood. 2017;130(Suppl 1):214.
20. Roy DC, Lachance S, Cohen S, et al. Allodepleted T-cell immunotherapy after haploidentical hematopoietic stem cell transplantation without severe acute graft-versus-host disease (GVHD) in the absence of GVHD prophylaxis. Br J Haematol. 2019;186(5):754-766.
21. Ciceri F, Bonini C, Stanghellini MT, et al. Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I/II study. Lancet Oncol. 2009;10(5):489-490.
22. Zhou X, Dott G, Krance RA, et al. Inducible caspase-9 suicide gene controls adverse effects from allogeneic T cells after haploidentical stem cell transplantation. Blood. 2015;125(20):4105-4113.
23. Ciurea SO, Zhang MJ, Bacigalupo AA, et al. Haploidentical transplant with posttransplant cyclophosphamide vs matched unrelated donor transplant for acute myeloid leukemia. Blood. 2015;126(5):1033-1040.
24. Bashey A, Zhang X, Jackson K, et al. Comparison of Outcomes of Hematopoietic Cell Transplants from T-Replete Haploidentical Donors Using Post-Transplant Cyclophosphamide with 10 of 10 HLA-A,-B,-C,-DRB1, and -DQB1 Allele-Matched Unrelated Donors and HLA-Identical Sibling Donors: A Multivariable Analysis Including Disease Risk Index. Biol Blood Marrow Transplant. 2016;22(1):125-133.
25. McCurdy SR, Kasamom YL, Kanaky CG, et al. Comparable composite endpoints after HLA-matched and HLA-haploidentical transplantation with post-transplantation cyclophosphamide. Haematologica. 2017;102(2):391-400.
26. Solomon SR, Szemore CA, Zhang X, et al. Impact of Donor Type on Outcome after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia. Biol Blood Marrow Transplant. 2016;22(10):1816-1822.
27. Wang Y, Liu DH, Xu LP, et al. Superior graft-versus-leukemia effect associated with transplantation of haploidentical compared with HLA-identical sibling donor grafts for high-risk acute leukemia: an historic comparison. Biol Blood Marrow Transplant. 2011;17(6):521-530.
28. Zeidan AM, Forde PM, Symons H, et al. HLA-haploidentical donor lymphocyte infusions for patients with relapsed hematologic malignancies after related HLA-haploidentical bone marrow transplantation. Biol Blood Marrow Transplant. 2014;20(3):314-318.
29. Ghiso A, Raiola AM, Gualandi F, et al. DLI after haploidentical BMT with post-transplant CY. Bone Marrow Transplant. 2015;50(1):56-61.
30. Goldsmith MR, Slade M, D’Persio JF, et al. Donor-lymphocyte infusion following haploidentical hematopoietic cell transplanta-
Donor lymphocyte infusion in haplo-HCT

31. Yan CH, Liu DH, Liu KY, et al. Risk stratification-directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119(14):3256-3262.

32. Yan CH, Liu QF, Wu DP, et al. Prophylactic Donor Lymphocyte Infusion (DLI) Followed by Allogeneic Disease-Matched Donor T-Cell Replete/Host-Disease-Guided Multiple DLI's Could Improve Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Refractory/Relapsed Acute Leukemia. Biol Blood Marrow Transplant. 2017;23(8):1311-1319.

33. Yan CH, Wang JZ, Liu DH, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Eur J Haematol. 2015;94(1):304-314.

34. Ma YR, Xu LF, Zhang XH, et al. Comparable post-relapse outcomes between haploidentical and HLA-matched related donor hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017;52(3):409-414.

35. Mo XD, Zhang XH, Xu LF, et al. Comparison of outcomes after donor lymphocyte infusion with or without prior chemotherapy for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2017;96(5):829-838.

36. Mo XD, Zhang XH, Xu LF, et al. Salvage chemotherapy followed by granulocyte colony-stimulating factor-primed donor lymphocyte infusion with graft-vs-host disease control for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: prognostic factors and clinical outcomes. Eur J Haematol. 2016;96(5):297-308.

37. He QQ, Qin YZ, Zhang XH, et al. Minimal residual disease monitoring and preemptive immunotherapy in myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Ann Hematol. 2016;95(9):1231-1240.

38. Huang XJ, Liu DH, Liu KY, et al. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haploidentical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92(5):414-417.

39. Yan CH, Xu LF, Liu DH, et al. Low-dose methotrexate may preserve a stronger antileukemia effect than that of cyclophosphamide after modified donor lymphocyte infusion in unmanipulated haploidentical HSCT. Clin Transplant. 2015;29(7):694-605.

40. Buckley JA, Wood BL, Oibus M, et al. Minimal residual disease prior to allogeneic hematopoietic cell transplantation in acute myeloid leukemia: a meta-analysis. Bone Marrow Transplant. 2017;52(9):445-451.

41. Shen Z, Gu X, Mao W, et al. Influence of pre-transplant minimal residual disease on prognosis after allo-SCT for patients with acute lymphoblastic leukemia: systematic review and meta-analysis. BMC Cancer. 2018;18(3):755.

42. Canaan J, Labopin M, Huang XJ, et al. Minimal residual disease status predicts outcome of acute myeloid leukemia patients undergoing T-cell replete haploidentical transplantation. Blood. 2015;126(14):2788-2792.

43. Lee HC, Saliba RM, Rondon G, et al. Mixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndrome. Biol Blood Marrow Transplant. 2015;21(11):1948-1954.

44. Koreth J, Kim HT, Nikolowos S, et al. Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survival. Biol Blood Marrow Transplant. 2021;44(10):1516-1521.

45. Solomon SR, Szemere CA, Zhang X, et al. Preemptive DLI without withdrawal of immunosuppression to promote complete donor T-cell chimerism results in favorable outcomes for high-risk older recipients of allogeneic reduced-intensity unrelated donor allogeneic transplant: a prospective phase II trial. Bone Marrow Transplant. 2014;49(5):616-621.

46. Di Grazia C, Pozzi S, Gerosa S, et al. Wilms Tumor 1 Expression and Preemptive Immunotherapy in Patients with Acute Myeloid Leukemia Undergoing an Allogeneic Hemopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2016;22(7):1242-1246.

47. Tan Y, Du K, Luo Y, et al. Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion. 2014;54(6):1499-1506.

48. Shah NV, Jorgensen JK, Saliba RM, et al. Early Post-Transplant Minimal Residual Disease Assessment Improves Risk Stratification in Acute Myeloid Leukemia. Biol Blood Marrow Transplant. 2018;24(7):1514-1520.

49. Keil F, Haas OA, Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual disease predicts aplasia. Blood. 1997;89(9):3113-3117.

50. Schmid C, Schleuning M, Lederose G, et al. Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome. J Clin Oncol. 2005;23(24):5675-5687.

51. Tsigiotis P, Liga M, Girkas K, et al. Low-dose alemtuzumab for GVHD prevention followed by prophylactic donor lymphocyte infusions in high-risk leukemia. Bone Marrow Transplant. 2017;52(8):445-451.

52. Maschan M, Blagov S, Shelkhova L, et al. Low-dose donor memory T-cell infusion after TCR alpha/beta depleted unrelated and haploidentical transplantation: results of a pilot trial. Bone Marrow Transplant. 2018;53(6):264-273.

53. Schmid C, Labopin M, Schaap N, et al. Prophylactic donor lymphocyte infusion after allogeneic stem cell transplantation in acute leukemia - a matched pair analysis by the Acute Leukaemia Working Party of EBM. Br J Haematol. 2018;185(4):762-767.

54. Cao XN, Lin J. Donor lymphocyte infusion for prevention of relapse after unmanipulated haploidentical PBSCT for very high-risk hematologic malignancies. Ann Hematol. 2018;97(1):185-193.

55. Jaiswal SR, Zaman S, Nedunchezhian M, et al. CD34+ enriched donor cell infusions after post-transplantation cyclophosphamide for haploidentical transplantation of advanced myeloid malignancies is associated with prompt reconstitution of mature natural killer cells and regulatory T cells with reduced incidence of acute graft versus host disease: A pilot study. Cytotherapy. 2017;19(4):531-542.

56. Jaiswal SR, Zaman S, Chakrabarti A, et al. Improved Outcome of Refractory/Relapsed Acute Myeloid Leukemia after Post-Transplantation Cyclophosphamide-Based Haploidentical Transplantation with Myeloid Differentiation and Early Prophylactic Granulocyte Colony-Stimulating Factor-Mobilized Donor Lymphocyte Infusions. Biol Blood Marrow Transplant. 2016;22(10):1867-1875.

57. Yan CH, Wang Y, Wang JZ, et al. Minimal residual disease- and graft-vs-host disease-guided multiple consolidation chemotheraphy and donor lymphocyte infusion prevent second acute leukemia relapse after allo-transplant. J Hematol Oncol. 2016;9(1):87.

58. Nagler A, Ackerstein A, Or R, et al. Adoptive immunotherapy with haploidentical allogeneic peripheral blood mononuclear cells in relapsing/relapsing autologous bone marrow transplantation. Exp Hematol. 2000;28(11):1225-1231.

59. Call SK, Kasow KA, Barfield R, et al. Total and active rabbit antithymocyte globulin (rATG, Thymoglobulin) pharmacokinetics in pediatric patients undergoing unrelated donor bone marrow transplantation. Biol Blood Marrow Transplant. 2009;15(5):274-278.

60. Gilman AL, Leung W, Cowan MJ, et al. Donor lymphocyte infusion and methotrexate for immune recovery after T-cell deple- ted haploidentical transplantation. Am J Hematol. 2018;93(2):169-178.

61. Martelli MF, Di Ianni M, Ruggeri L, et al. HLA-haploidentical transplantation with regulatory and conventional T-cell adoptive immunotherapy prevents acute leukemia relapse. Blood. 2014;124(4):658-664.

62. Duoden KJ, Cachali G, et al. Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery. Blood. 2009;113(19):4771-4779.

63. Ferruccio K, Tosti A, Burchieli E, et al. Transferring functional immune responses to pathogens after haploidentical hematopoietic hematopoietic transplantation. Blood. 2005;106(15):4597-4606.

64. Ederger M, Hoffmann P, Ermann J, et al. CD54-CD44-C55+ regulatory T cells prevent graft-versus-tumor activity while inhibiting graft-versus-host disease after bone marrow transplantation. Nat Med. 2003;9(9):1144-1150.

65. Lewalle P, Triftt A, Delforge A, et al. Donor lymphocyte infusions in adult haploidentical transplantation: a dose finding study. Bone Marrow Transplant. 2005;35(11):989-993.

66. Wang Y, Liu DH, Xu LE, et al. Prevention of relapse using granulocyte CSF-primed FBCs following HLA-mismatched/haploidentical, T-cell-replete hematopoietic SCT in patients with high-risk acute leukemia: a retrospective risk-factor analysis. Bone Marrow Transplant. 2012;47(8):1099-1104.
67. Cauchois R, Castagna I, Pagliardini T, et al. Prophylactic donor lymphocyte infusions after haploidentical haematopoietic stem cell transplantation for high risk haematological malignancies: a retrospective bicentric analysis of allogeneic stem cell transplantation. Br J Haematol. 2019;185(3):570-573.

68. Dazzi F, Sydlo RM, Cross NC, et al. Durability of responses following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;96(2):2712-2716.

69. Tan TL, Liu DH, Xu LF, et al. Modified donor lymphocyte infusion-associated acute graft-versus-host disease after haploidentical T-cell-replete hematopoietic stem cell transplantation: incidence and risk factors. Clin Transplant. 2012;26(6):686-687.

70. Jun HX, Jun CY, Yu ZX. In vivo induction of T-cell hyporesponsiveness and alteration of immunological cells of bone marrow grafts using grafts grown in colony stimulator factor. Haematologica. 2004;89(12):1517-1524.

71. Wen Q, Kong Y, Zhao HY, et al. G-CSF-induced macrophage polarization and mobilization of allogeneic acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant. 2019;54(9):1419-1433.

72. Chen SH, Li X, Huang X. Effect of recombinant human granulocyte colony-stimulating factor on T-lymphocyte function and the mechanism of this effect. Int J Hematol. 2004;79(2):178-184.

73. Huang X, Chen RJ, Yao XY, et al. Maintaining hyporesponsiveness and polarization potential of T cells after in vitro mixture of G-CSF mobilized peripheral grafts and G-CSF primed peripheral grafts in different proportions. Transplant Immunol. 2007;17(3):198-197.

74. Gómez-De León A, Colunga Pedraza FR, García-Camarrillo DE, et al. Donor Lymphocyte Infusion from G-CSF-Primed, Unmanipulated Whole Blood Is Safe and Improves Chimerism in HLA-Matched and Haploidentical Hematopoietic Transplantation. Blood. 2016;128(24):2486-2495.

75. Bracci L, Moschella F, Sestili P, et al. Cyclophosphamide enhances the antitumor efficacy of adoptively transferred immune cells and affects the induction of cytokine expression, B-cell and T-cell homeostatic proliferation, and specific tumor infiltration. Clin Cancer Res. 2007;13(2 Pt 1):644-653.

76. He F, Warlick E, Miller JS, et al. Lymphodepleting chemotherapy with donor lymphocyte infusion post-allogeneic HCT for hematological malignancies is associated with severe, but therapy-responsive aCoHD. Bone Marrow Transplant. 2016;51(5):1107-1112.

77. Goodayr O, Agathanggelou A, Novitzky-Basso I, et al. Induction of a CD8+ T-cell response to the MAGE cancer testis antigen by combined treatment with azacitidine and sodium valproate in patients with acute myeloid leukemia and myelodysplasia. Blood. 2010;116(11):1908-1913.

78. Gerecievicius T, Yakooby-Agha I, Tabrizi R, et al. Prospective Phase II Study of Prophylactic Azacitidine and Donor Lymphocyte Infusions Following Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome. Blood. 2016;128(2):1162.

79. Schreiber T, Rautenberg C, Haas R, Kobbe R, Hoffmann, et al. Hypomethylating agents after allogeneic stem cell transplantation. Stem Cell Invest. 2016;3(3):34.

80. Schroeder T, Czibere A, Platekischer U, et al. Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia. 2013;27(6):1229-1235.

81. Schroeder T, Rautenberg C, Kruger W, et al. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group. Ann Hematol. 2016;95(1):1590-1594.

82. Bazazbachi A, Labopin M, Battaglia G, et al. Allogeneic Stem Cell Transplantation for FLT3-Mutated Acute Myeloid Leukemia. In vivo T-Cell Depletion and Posttransplant Sorafenib Maintenance Improve Survival. A Retrospective Acute Leukemia Working Party-European Society for Blood and Marrow Transplant Study. Clin Hematol Int. 2019;41(1):105-118.

83. Canaan J. Management of AML Beyond *3 + 7* in 2019. Clin Hematol Int. 2019;1:10-110.

84. Schmidt SA, Holter Chakrabarty J, Liu Y, et al. Tumour-specific immunotherapies with or without Donor Lymphocyte Infusion Continue to Provide Long-Term Survival after Relapse of Chronic Myeloid Leukemia Following Hematopoietic Cell Transplantation. Blood. 2018;132(Suppl 1):1704.

85. Vago L, Ferna SK, Zanussi M, et al. Loss of mismatched HLA in leukemia after stem-cell transplantation. N Engl J Med. 2009;361(5):476-487.

86. Crucitti L, Crociolito R, Toftanin C, et al. Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched ACR or partially incompatible hematopoietic stem cell transplantation. Leukemia. 2015;29(5):1143-1152.

87. Imus PH, Blackford AL, Bettinotti M, et al. Major Histocompatibility Mismatch and Donor Choice for Second Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant. 2017;23(11):1857-1894.

88. McCurdy SB, Iglehart JS, Batista DA, et al. Loss of the Mismatched Human Leukocyte Antigen Haplotype in Two Acute Myelogenous Leukemia Relapses after Haploidentical Bone Marrow Transplantation with Posttransplantation Cyclophosphamide. Leukemia. 2016;30(10):2102-2106.

89. Russo A, Oliveira G, Berglund S, et al. NK cell recovery after haploidentical HSCT with posttransplant cyclophosphamide: dynamics and clinical implications. Blood. 2018;131(2):247-262.

90. Jaiswal SB, Bhakuni P, Bharadwaj P, et al. CTLA4ig Primed Donor Lymphocyte Infusions (DLI): A Novel Approach to Natural Killer Cell Immunotherapy Following a Haploidentical PBSCT Transplantation for Advanced Hematological Malignancies. Blood. 2017;130(Suppl 1):4468.

91. Ciurea SO, Scharer JR, Bassett R, et al. Phase I clinical trial using mAB.L1 ex vivo expanded donor-derived NK cells after haploidentical transplantation. Blood. 2017;130(16):1857-1868.

92. Szczepanski MJ, Szajnik M, Welsh A, et al. Induction of donor lymphocyte infusions following mismatched stem cell transplantation. Biol Blood Marrow Transplant. 2006;12(12):1295-1301.